Transdermal lidocaine patch 5 percent and lidocaine cream 5 percent: a PK/PD approach in the horse

• Autorzy: Andreoni V. , Giorgi M.
• Języki publikacji: EN

Abstrakty

EN

Transdermal absorption of four lidocaine (L) patches 5% was compared to the transdermal absorption of L cream 5% to evaluate the pharmacokinetics of the two formulations applied on the same anatomical region under dressing in eight horses. The animals were also assessed for the adequacy of analgesia after patches and cream removal, using a psychophysical method by pricking the patient’s skin to assess the response to pain according to a visual analogue scale. Horses were randomly assigned to four treatment groups: in groups I and II four L patches were applied for a period of 24 hours with and without alcohol pre-cleaning respectively; in group III, 5% L cream was applied every two hours over a period of 24 hours on the same anatomical site. Group IV was the control. No clinical side effects were noted with both formulations. L was detectable in plasma within 6 and 24 hours after patch application and the highest plasma concentrations were reached between 12 and 18 hours. The use of alcohol to pre-clean the skin appeared to reduce the transdermal drug absorption over time. The plasma drug level, after L cream application, reached the highest plasma concentration after 24 hours. Pain assessment after L patch or L cream application, revealed a decreased response when the L cream was used. The result of this study shows that there is an overall lower absorption from the L patches compared with the L cream in horses. Also the L cream treatment reduces significantly the intensity of pain quality as measured by the visual analogue scale.

• Wydawca: -
• Czasopismo: Medycyna Weterynaryjna
• Rocznik: 2009
• Tom: 65
• Numer: 09
• Opis fizyczny: p.612-616,fig.,ref.

Twórcy

autor

Andreoni V.

• Veterinary Anaesthesia and Intensive Care, UCD Veterinary Sciences Centre, University College Dublin, Belfield, Dublin 4, Ireland

autor

Giorgi M.

Bibliografia

• 1.Bidwell L. A., Wilson D. V., Caron J. P.: Lack of systemic absorption of lidocaine from 5% patches placed on horses. Vet. Anaesth. Analg. 2007, 34, 443-446.
• 2.Chien Y. W., Xu H. L., Chiang C. C., Huang Y. C.: Transdermal controlled administration of indomethacin. I. Enhancement of skin permeability. Pharm. Res. 1988, 5, 103-106.
• 3.Curatolo M., Petersen-Felix S., Arendt-Nielsen L.: Assessment of regional analgesia in clinical practice and research. Br. Med. Bull. 2005, 71, 61-76.
• 4.Dickey E. J., McKenzie H. C. 3rd, Brown K. A., de Solis C. N.: Serum concentrations of lidocaine and its metabolites after prolonged infusion in healthy horses. Equine Vet. J. 2008, 40, 348-352.
• 5.Doherty T. J., Frazier D. L.: Effect of intravenous lidocaine on halothane minimum alveolar concentration in ponies. Equine Vet. J. 1998, 30, 300-303.
• 6.Endo Pharmaceuticals: 24-hour application of the lidocaine patch 5% for 3 consecutive days is safe and well tolerated in healthy adult men and women. Pain Med. 2002, 2, 172.
• 7.Erkert R. S., Macallister C. G., Campbell G., Payton M. E., Shawley R., Clarke C. R.: Comparison of topical lidocaine/prilocaine anesthetic cream and local infiltration of 2% lidocaine for episioplasty in mares. J. Vet. Pharmacol. Ther. 2005, 28, 299-304.
• 8.Flecknell P. A., Liles J. H., Williamson H. A.: The use of lignocaine-prilocaine local anaesthetic cream for pain-free venepuncture in laboratory animals. Lab. Anim. 1990, 24, 142-146.
• 9.Friend D., Catz P., Heller J., Reid J., Baker R.: Transdermal delivery of levonorgestrel: I. Alkanols as permeation enhancers in vitro. J. Control Release 1988, 7, 243-250.
• 10.Gammaitoni A. R., Alvarez N. A., Galer B. S.: Pharmacokinetics and safety of continuously applied lidocaine patches 5%. Am. J. Health Syst. Pharm. 2002, 59, 2215-2220.
• 11.Gammaitoni A. R., Alvarez N. A., Galer B. S.: Safety and tolerability of the lidocaine patch 5%, a targeted peripheral analgesic: a review of the literature. J. Clin. Pharmacol. 2003, 43, 111-117.
• 12.Harada K., Murakami T., Yata N., Yamamoto S.: Role of intercellular lipids in stratum corneum in the percutaneous permeation of drugs. J. Invest. Dermatol. 1992, 99, 278-282.
• 13.Kao J., Carver M. P.: Cutaneous metabolism of xenobiotics. Drug Metab. Rev. 1990, 22, 363-410.
• 14.Ko J., Weil A., Maxwell L., Kitao T., Haydon T.: Plasma concentrations of lidocaine in dogs following lidocaine patch application. J. Am. Anim. Hosp. Assoc. 2007, 43, 280-283.
• 15.Ko J. C., Maxwell L. K., Abbo L. A., Weil A. B.: Pharmacokinetics of lidocaine following the application of 5% lidocaine patches to cats. J. Vet. Pharmacol. Ther. 2008, 31, 359-367.
• 16.Kushla G. P., Zatz J. L.: Evaluation of a noninvasive method for monitoring percutaneous absorption of lidocaine in vivo. Pharm. Res. 1990, 7, 1033-1037.
• 17.Liu P., Higuchi W. I., Ghanem A. H., Good W. R.: Transport of beta-estradiol in freshly excised human skin in vitro: diffusion and metabolism in each skin layer. Pharm. Res. 1994, 11, 1777-1784.
• 18.Macallister C. G., Campbell G., Payton M. E., Shawley R., Clarke C. R.: Comparison of topical lidocaine/prilocaine anesthetic cream and local infiltration of 2% lidocaine for episioplasty in mares. J. Vet. Pharmacol. Ther. 2005, 28, 299-304.
• 19.Milligan M., Kukanich B., Beard W., Waxman S.: The disposition of lidocaine during a 12-hour intravenous infusion to postoperative horses. J. Vet. Pharmacol. Ther. 2006, 29, 495-499.
• 20.Mills P. C., Cross S. E.: Regional differences in the in vitro penetration of hydrocortisone through equine skin. J. Vet. Pharmacol. Ther. 2006, 29, 25-30.
• 21.Mills P. C., Cross S. E.: Transdermal drug delivery: basic principles for the veterinarian. Vet. J. 2006, 172, 218-233.
• 22.Monteiro-Riviere N. A., Inman A. O., Mak V., Wertz P., Riviere J. E.: Effect of selective lipid extraction from different body regions on epidermal barrier function. Pharm. Res. 2001, 18, 992-998.
• 23.Morton D. B., Griffiths P. H.: Guidelines on the recognition of pain, distress and discomfort in experimental animals and an hypothesis for assessment. Vet. Rec. 1985, 116, 431-436.
• 24.Pasero C.: Lidocaine patch 5%. Am. J. Nurs. 2003, 103, 75, 77-78.
• 25.PDR - Physicians' Desk reference. 50th edition Medical Economics Company 1996, 545-546.
• 26.Pfister W. R., Dean S., Hsieh S. T.: Permeation enhancers compatible with transdermal delivery systems. Part 1: selection and formulation considerations. Pharm. Thecnol. 1990, 8, 132-140.
• 27.Riviere J. E., Papich M. G.: Potential and problems of developing transdermal patches for veterinary applications. Adv. Drug Deliv. Rev. 2001, 50, 175-203.
• 28.Sawynok J.: Topical analgesics in neuropathic pain. Curr. Pharm. Des. 2005, 11, 2995-3004.
• 29.Wagner K. A., Gibbon K. J., Strom T. L., Kurian J. R., Trepanier L. A.: Adverse effects of EMLA (lidocaine/prilocaine) cream and efficacy for the placement of jugular catheters in hospitalized cats. J. Feline Med. Surg. 2006, 8, 141-144.
• 30.Walker R. B., Smith E. W.: The role of percutaneuos penetration enhancers. Adv. Drug Deliv. Rev. 1996, 18, 295-301.
• 31.Wallace M. S., Dyck J. B., Rossi S. S., Yaksh T. L.: Computer-controlled lidocaine infusion for the evaluation of neuropathic pain after peripheral nerve injury. Pain 1996, 66, 69-77.
• 32.Weil A. B., Ko J., Inoue T.: The use of lidocaine patches in dogs and cats. Compend. Contin. Educ. Vet. 2007, 29, 208-210, 212, 214-216.
• 33.Weiland L., Croubels S., Baert K., Polis I., De Backer P., Gasthuys F.: Pharmacokinetics of a lidocaine patch 5% in dogs. J. Vet. Med. A Physiol. Pathol. Clin. Med. 2006, 53, 34-39.
• 34.Wilcke J. R., Davis L. E., Neff-Davis C. A.: Determination of lidocaine concentrations producing therapeutic and toxic effects in dogs. J. Vet. Pharmacol. Ther. 1983, 6, 105-112.

Uwagi

Rekord w opracowaniu